title: Polycystic ovary syndrome: an overview.
abstract: Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age. It affects 6% to 7% of the population and is characterized by hyperandrogenism and ovarian dysfunction. Women with the disorder often present with insulin resistance and obesity, making it importance for health care providers to monitor closely for signs and symptoms of metabolic syndrome and type 2 diabetes. Treatments are targeted toward improving insulin tolerance, reducing signs and symptoms of hyperandrogenism (hirsutism, anovulation, etc), restoring normal menstrual cycle function, and restoring fertility. Major treatment should include weight management through diet and exercise, regardless of body mass index and might include concurrent drug therapy. It is important that pharmacists understand the underlying pathophysiology of the disease and the available treatments, in addition to the importance of reducing risk of metabolic syndrome/type 2 diabetes, and cardiovascular disease in these patients.
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Whitaker@acphs.edu
authors.forename: Kristin Nadine
authors.initials: KN
authors.lastname: Whitaker
mesh_terms: D000818:Animals; D001835:Body Weight / Q000502:physiology; D015444:Exercise / Q000502:physiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007247:Infertility, Female / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D008659:Metabolic Diseases / Q000150:complications / Q000378:metabolism / Q000628:therapy; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000378:metabolism* / Q000628:therapy*
chemical_list: D007004:Hypoglycemic Agents